Eton Pharmaceutcials, Inc. 8-K Filings

Eton Pharmaceuticals entered into a material license agreement with Auson Pharmaceuticals for U.S. rights to ASN-001, a late-stage timolol topical gel for proliferating superficial infantile hemangiomas. Eton will pay an upfront license fee of $3.0 million within thirty days and will run a bioavailability bridging study, with plans to submit a New Drug Application in the second half of 2027.

Following FDA approval of ASN-001, Auson is eligible for a $5,000,000 milestone when annual net sales reach $80,000,000 and $10,000,000 when they reach $150,000,000, plus tiered royalties of 10%, 13% and 15% on cumulative lifetime net product sales across specified net sales tiers. A three‑arm Phase II/III trial in 168 patients showed elimination or near-elimination of infantile hemangiomas at week 24 in 56% of twice-daily and 42% of three-times-daily ASN-001 patients, versus 15% with placebo.

Eton positions ASN-001 as a topical therapy complementary to its systemic product HEMANGEOL, targeting an estimated 20,000 to 30,000 U.S. patients within a broader pool of more than 100,000 affected infants annually. If approved, ASN-001 is expected to be the first FDA-approved topical therapy for infantile hemangiomas and benefits from patent protection through 2044.

Eton Pharmaceuticals, Inc. appointed Danka Radosavljevic, age 42, as Chief Operating Officer on July 31, 2026. She has been with the company since 2017 and most recently served as Executive Vice President, Operations overseeing quality, product development, regulatory, supply chain and information systems.

Her compensation package includes an annual base salary of $520,800 and an annual discretionary incentive bonus with a target of 50% of base salary, contingent on corporate and/or individual performance targets to be approved by the Board of Directors.

Eton Pharmaceuticals reported submitting a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration to expand the indication of KHINDIVI (hydrocortisone) oral solution to younger pediatric patients. The new KHINDIVI formulation showed bioequivalence to ALKINDI SPRINKLE, an FDA-approved hydrocortisone granule formulation.

KHINDIVI is currently approved as replacement therapy for pediatric patients 5 years of age and older with adrenocortical insufficiency and is the only FDA‑approved oral hydrocortisone solution. Management comments that label expansion could potentially occur in the first half of 2027. Eton estimates approximately 10,000 pediatric adrenal insufficiency patients in the U.S. and highlights extensive safety warnings, including risks of adrenal crisis, hyperosmolarity, metabolic acidosis, growth retardation, Cushing’s syndrome, bone density loss, psychiatric effects, ophthalmic and gastrointestinal adverse reactions.

Eton Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 9, 2026. Stockholders elected Jenn Adams and Charles J. Casamento to the board for three-year terms and ratified Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026.

Eton Pharmaceuticals entered a supply and distribution agreement for exclusive U.S. commercialization rights to IMPAVIDO (miltefosine), an orphan drug for various forms of leishmaniasis. The initial term runs through March 31, 2032, with options for up to ten additional one-year renewals.

Eton will pay the supplier $4.25 million in fixed fees during the initial term and up to an additional $4.0 million tied to cumulative net sales milestones of $50 million, $100 million, $150 million and $200 million. The supplier receives 55% of net sales up to $7.0 million per year and 50% above that, while covering product and regulatory costs; Eton funds sales and marketing. Eton’s exclusive U.S. rights begin on September 26, 2026, and 2025 U.S. sales of IMPAVIDO were $8.1 million.

Eton Pharmaceuticals reported strong first-quarter 2026 results, with total net revenue of $24.3 million, up 40% from $17.3 million a year earlier, and product sales and royalties rising 73% to $24.3 million. Gross profit increased to $14.7 million from $9.9 million.

The company generated Adjusted EBITDA of $5.7 million, or 24% of revenue, versus $3.7 million and 21% a year ago. GAAP results swung to net income of $1.6 million from a $1.6 million loss, while non-GAAP net income rose to $4.5 million. Eton raised its 2026 revenue outlook to more than $120 million and now targets at least a 30% Adjusted EBITDA margin, supported by record product sales, launches of DESMODA and HEMANGEOL, and continued rare-disease pipeline progress.

Eton Pharmaceuticals filed a report describing the relaunch of HEMANGEOL (propranolol) Oral Solution, the only FDA‑approved treatment for infantile hemangioma, a rare pediatric vascular tumor that can be time‑sensitive.

The relaunch integrates the full Eton Cares patient support program, including $0 co‑pay for eligible commercially insured patients and expanded patient assistance. HEMANGEOL is an orphan drug typically started between five weeks and five months of age and used for about six months to help prevent complications. The company estimates approximately 5,000–10,000 infants in the United States are treated with HEMANGEOL each year and is using an exclusive rare disease specialty pharmacy distribution model to support timely access.

Eton Pharmaceuticals filed an 8-K to announce dosing of the first patient in a pilot clinical study of ET-700, its extended-release zinc acetate candidate for Wilson disease. The double-blinded, placebo-controlled trial in Denmark will follow 36 healthy volunteers over four weeks using 64Cu PET imaging to measure intestinal copper absorption.

The study compares GALZIN 50 mg three times daily, ET-700 75 mg twice daily plus one placebo dose, and placebo three times daily, with hepatic 64Cu uptake as the primary endpoint. Eton’s CEO said that, if approved, ET-700 could potentially exceed $100 million in peak annual U.S. sales and support simpler dosing for this lifelong condition.

Eton Pharmaceuticals announced a planned chief financial officer transition. Judith “Judy” Matthews has been appointed Executive Vice President, Accounting and Finance and will become Chief Financial Officer, Corporate Secretary, and Treasurer effective June 1, 2026, succeeding James Gruber. Gruber will remain CFO through May 31, 2026 and then serve under a six-month consulting agreement to support continuity.

Matthews’ compensation includes an annual base salary of $440,000, plus an annual discretionary bonus targeted at 45% of base salary, tied to corporate and/or individual performance goals approved by the board. As an inducement, she received a one-time option to purchase 37,000 shares of common stock, vesting in equal annual installments over four years, and will participate in standard executive benefit plans. The company states her selection was not made pursuant to any arrangement with another person and notes no disclosable family or related-party relationships.

Eton Pharmaceuticals entered into a sixth amendment to its credit agreement with SWK Funding LLC. The amendment lowers the loan’s interest rate from Secured Overnight Financing Rate (SOFR) plus 6.75% to SOFR plus 6.55% and reduces the SOFR floor from 5.0% to 2.75%.

The interest-only period was extended to November 2026, and Eton may choose to begin principal payments in May 2026 or defer them until November 2026. No fees were paid to SWK in connection with this amendment, and the loan’s maturity date remains in December 2027.

Eton Pharmaceuticals reported strong fourth quarter and full-year 2025 results, with total net revenues of $79.9 million, up from $39.0 million in 2024. Growth was driven by rare disease products including INCRELEX, ALKINDI SPRINKLE, GALZIN, and KHINDIVI.

Fourth quarter 2025 net revenues were $21.3 million, an 83% increase over the prior-year period, and gross profit rose to $13.1 million. Adjusted EBITDA for 2025 improved to $15.8 million from $2.9 million, while GAAP net loss was $4.6 million. The company posted fourth quarter GAAP net income of $1.5 million.

Eton highlighted the launch of DESMODA, acquisition of orphan drug HEMANGEOL, and advancing clinical programs for INCRELEX label expansion, KHINDIVI reformulation, ET-700, and AMGLIDIA. For 2026, it expects revenue to exceed $110 million with an Adjusted EBITDA margin of at least 30%, indicating confidence in continued growth and improving profitability.

Eton Pharmaceuticals has acquired U.S. commercialization rights to HEMANGEOL, an Orphan Drug for infantile hemangioma, through a licensing deal with Pierre Fabre Medicament Sas. Eton will pay $14.0 million upfront, plus an 8% royalty on net U.S. sales for the product’s patent life.

The company will buy about $1.5 million of inventory at closing and an estimated $0.7 million in May 2026, funded from existing cash. Pierre Fabre will distribute HEMANGEOL in the U.S. until April 30, 2026, after which Eton will take over. Management expects the transaction to be accretive to 2026 earnings.

According to IQVIA data, HEMANGEOL generated $11.7 million in U.S. sales in 2025. It is currently the only treatment indicated for proliferating infantile hemangiomas requiring systemic therapy, with an estimated 5,000–10,000 infants treated annually in the United States.

Eton Pharmaceuticals reported that the U.S. FDA has approved its New Drug Application for DESMODA (desmopressin acetate) Oral Solution to manage central diabetes insipidus, or arginine vasopressin deficiency, in patients of all ages. DESMODA is described as the first and only FDA‑approved oral liquid formulation of desmopressin, designed for precise, individualized dosing in a condition where careful titration is critical to maintaining water balance.

The product is supplied as a ready‑to‑use 0.05 mg/mL solution that avoids tablet splitting, crushing, refrigeration, mixing, or shaking. Eton estimates more than 13,000 U.S. patients have central diabetes insipidus, including 3,000–4,000 pediatric patients, and expects DESMODA peak annual sales of $30–50 million. DESMODA will be promoted by Eton’s existing pediatric endocrinology rare disease team and is expected to be available on March 9 exclusively through specialty pharmacy Anovo, which will run the Eton Cares support program with services such as prescription fulfillment, insurance investigation, education, and financial assistance.

Eton Pharmaceuticals reported that it has licensed U.S. marketing rights to an ultra-rare disease product candidate. The product, once approved, is expected to be the first and only generic alternative to an existing treatment for an ultra-rare condition affecting fewer than 100 patients in the United States.

The licensing arrangement was disclosed through a press release dated February 2, 2026, which is attached as an exhibit to the report.

Eton Pharmaceuticals, Inc. filed an amended Form 8-K to add required financial information related to its completed acquisition of the Increlex® product rights from Ipsen S.A. The amendment supplies audited abbreviated financial statements for INCRELEX as of and for the years ended December 31, 2022 and 2023, along with unaudited abbreviated financial statements as of September 30, 2024 and for the nine months ended September 30, 2023 and 2024. It also includes unaudited pro forma condensed combined financial statements for Eton and INCRELEX for the nine-month periods ended September 30, 2023 and 2024, helping readers see how the acquisition would have affected the company’s historical financials. Other disclosures in the original report remain unchanged.

Eton Pharmaceuticals furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1. The filing also discusses the use of non-GAAP Adjusted EBITDA, which management uses for planning, evaluating performance, communicating with the board and investors, and assessing acquisitions and comparative net sales. The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed a Form 8-K to disclose a material event under Item 8.01. On 8 July 2025, the company announced that the U.S. Food and Drug Administration (FDA) accepted for review its New Drug Application (NDA) for ET-600, a proprietary, patented oral solution formulation of desmopressin. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 25 February 2026.

The acceptance of the NDA formally places ET-600 into the FDA review queue and confirms that the submission is sufficiently complete for substantive review. While no financial data were provided in this filing, ET-600 represents a potential commercial asset that could expand Eton’s rare disease/critical care portfolio if ultimately approved. The company attached the related press release as Exhibit 99.1 and provided routine exhibit and signature information.

Key points for investors:

• NDA accepted: De-risks the regulatory pathway by moving ET-600 from development to formal FDA review.
• PDUFA date set: Establishes a definitive decision timeline (≈7.5 months from filing date).
• No financial metrics: The 8-K contains no sales, earnings, or cost guidance related to ET-600 or the broader business.
• Next catalyst: Potential FDA approval decision on or before 25 February 2026.

The filing is non-dilutive—it involves no financing, equity issuance, or debt—and does not alter previously reported financial statements. Nonetheless, regulatory progress on ET-600 can influence future revenue forecasts and valuation multiples once market potential data are released.

Eton Pharmaceuticals (NASDAQ:ETON) filed an 8-K to disclose that the company will be added to the Russell 3000 and Russell 2000 indexes effective after the U.S. market close on June 27 2025.

The filing, made under Item 8.01, includes a press release (Exhibit 99.1) and signals broader passive fund ownership, higher trading liquidity and increased institutional visibility. No financial results, strategic shifts or governance changes were reported.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed a Form 8-K to disclose an auditor transition effective 13 June 2025.

Dismissal of Crowe LLP: The Audit Committee terminated Crowe LLP after only one audit cycle (FY-2024). Crowe’s 2024 opinion was clean (no adverse or qualified opinion), and the firm reported no disagreements or reportable events with management under Item 304(a)(1) of Regulation S-K. Crowe’s required concurrence letter is attached as Exhibit 16.1.

Appointment of Grant Thornton LLP: The Audit Committee simultaneously engaged Grant Thornton LLP as the new independent registered public accounting firm for FY-2025. The company confirms that, during FY-2023, FY-2024, and the subsequent interim period, it did not consult Grant Thornton on any accounting matters or potential opinions prior to the appointment.

Investor takeaways:

• The change appears procedural; the absence of disagreements reduces immediate red-flag risk.
• Auditor turnover after one year may still prompt investors to monitor governance continuity and upcoming audit fees or timelines.
• No financial restatements, outlook changes, or earnings data were disclosed in this filing.